Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals Inc (NY: AMRX )

4.660 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
Amneal to Virtually Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Pharmaceuticals, inc (AMRX) Q3 2021 Earnings Call Transcript
AMRX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Amneal Posts Mixed Bag Q3 Earnings; Acquires Puniska To Bolster Injectable Business
Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q3 revenue of $529 million, a marginal increase of 2% Y/Y, missing the consensus of $545.06 million. The increase was driven... 
Via Benzinga
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Exposures Pension
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Amneal Reports Third Quarter 2021 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Mark Cuban-Owned Company To Launch Pharmacy Benefit Management Services
Billionaire investor Mark Cuban is funding a new company focused on selling generic pharmaceuticals at a transparent fixed-rate markup. What Happened: The Mark Cuban Cost Plus... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Amneal to Report Third Quarter 2021 Results on November 3, 2021
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Virtually Participate at Morgan Stanley 19th Annual Global Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures COVID-19
22 Stocks Moving in Thursday's Pre-Market Session
Gainers Good Works Acquisition Corp. (NASDAQ: GWAC) rose 29.8% to $13.01 in pre-market trading. Good Works Acquisition and Cipher Mining reported shareholder approval of business... 
Via Benzinga
Amneal's Parkinson's Candidate Shows Efficacy In Pivotal Trial
Amneal Pharmaceuticals Inc (NYSE: AMRX) announced topline data from the Phase 3 RISE-PD trial evaluating IPX-203 in patients with Parkinson's disease who have... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Ascendis Pharma (NASDAQ:ASND) st... 
Via Benzinga
Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
From Amneal Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Exposures COVID-19
Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Pharmaceuticals, inc (AMRX) Q2 2021 Earnings Call Transcript
AMRX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Amneal Q2 Earnings Tops Estimates; Backs FY21 Guidance
Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q2 revenue of $535 million, an increase of 15% Y/Y, beating the consensus of $523.25 million. Sales growth was driven by... 
Via Benzinga
Amneal Pharmaceuticals: Q2 Earnings Insights
Shares of Amneal Pharmaceuticals (NYSE:AMRX) moved higher by 0.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share... 
Via Benzinga
Amneal Reports Second Quarter 2021 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives Approval for Generic TobraDex®
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report Second Quarter 2021 Results on August 9, 2021
From Amneal Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated... 
Via Benzinga
Amneal's Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer
The FDA has accepted for review Amneal Pharmaceuticals Inc's (NYSE: AMRX) marketing application seeking approval for Bevacizumab, under Section 351(k) pathway... 
Via Benzinga
Exposures Product Safety
Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Virtually Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.